GRI Bio, Inc. GRI
At closeNov 11, 2026, 4:00 PM EST
After hours · Nov 11, 4:00 PM ET
- YTD
- -73.55%
- 1 year
- -96.47%
- Market cap
- 4.00M
- EPS (ttm)
- -14.71
- Shares out
- 8.93M
- Forward P/E
- -0.29
- YTD return
- -73.55%
- 1-year return
- -96.47%
- Volume
- 56.06K
- Avg volume
- 228.13K
- Open
- 1.90
- Previous close
- 1.89
- Day's range
- 1.76 – 1.97
- 52-week range
- 1.36 – 64.12
- Analysts
- Strong Buy
- Price target
- 11.50 (+528.4%)
5D +0.30 (+19.61%)
Key statistics
- Enterprise value
- -3.95M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.87M
- Total cash
- 6.35M
- Total debt
- 141.00K
- Return on equity
- -189.06%
- Short % of float
- 25.11%
- 50-day average
- 0.76778
- 200-day average
- 2.82
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 11.50
- Target (high)
- 13.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.32.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | HC Wainwright & Co. | init | — | Buy |
| Dec 5, 2024 | Ascendiant Capital | main | Buy | Buy |
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gribio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on GRI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGRO ALBERT | Officer | Stock Award(Grant) | Apr 20, 2023 | 172,189 |
| CHATURVEDI VIPIN | Officer | Stock Award(Grant) | Apr 20, 2023 | 172,189 |
| HERTZ WALTER MARC | Chief Executive Officer | Stock Award(Grant) | Apr 20, 2023 | 385,510 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.80% | 71,647 | 54.01K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.36% | 32,272 | 24.33K | Sep 29, 2024 |
| HRT Financial LP | 0.16% | 13,965 | 10.53K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.13% | 11,847 | 8.93K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.05% | 4,464 | 3.36K | Sep 29, 2024 |
| Blackrock Inc. | 0.04% | 3,596 | 2.71K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.13% | 11,628 | 8.77K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 203 | 153 | Sep 29, 2024 |